DAFNA Capital Management LLC Purchases 249,275 Shares of Inogen, Inc $INGN

Key Points

• DAFNA Capital Management LLC significantly increased its holdings in Inogen, Inc by 119.4%, owning a total of 458,065 shares after purchasing an additional 249,275 shares in the first quarter.
• Analysts have mixed opinions about Inogen, with a consensus rating of "Moderate Buy" and a price target averaging $11.00, while some raised and others lowered their targets recently.
• Inogen recently reported better-than-expected quarterly earnings, with a revenue of $92.28 million, surpassing analyst estimates of $90.40 million.

DAFNA Capital Management LLC lifted its position in shares of Inogen, Inc (NASDAQ:INGN - Free Report) by 119.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 458,065 shares of the medical technology company's stock after purchasing an additional 249,275 shares during the period. Inogen accounts for about 0.9% of DAFNA Capital Management LLC's holdings, making the stock its 26th biggest position. DAFNA Capital Management LLC owned approximately 1.70% of Inogen worth $3,266,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in INGN. Nuveen LLC bought a new stake in shares of Inogen during the 1st quarter worth $1,097,000. Royce & Associates LP increased its holdings in Inogen by 42.8% in the 1st quarter. Royce & Associates LP now owns 444,457 shares of the medical technology company's stock worth $3,169,000 after acquiring an additional 133,258 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Inogen by 25.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company's stock worth $5,574,000 after acquiring an additional 123,208 shares during the last quarter. Monaco Asset Management SAM increased its holdings in Inogen by 119.1% in the 1st quarter. Monaco Asset Management SAM now owns 167,594 shares of the medical technology company's stock worth $1,195,000 after acquiring an additional 91,094 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Inogen by 162.5% in the 4th quarter. Millennium Management LLC now owns 143,653 shares of the medical technology company's stock worth $1,317,000 after acquiring an additional 88,924 shares during the last quarter. 89.94% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. B. Riley assumed coverage on Inogen in a report on Monday, June 16th. They issued a "buy" rating and a $14.00 price objective for the company. Needham & Company LLC raised Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price for the company in a report on Thursday, May 22nd. Finally, Stifel Nicolaus reduced their target price on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a report on Thursday, May 8th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $11.00.

Inogen Trading Up 0.4%

Shares of INGN opened at $7.99 on Friday. The company has a market cap of $216.05 million, a PE ratio of -7.54 and a beta of 1.72. The stock has a 50-day moving average price of $7.04 and a 200-day moving average price of $7.21. Inogen, Inc has a 12-month low of $5.70 and a 12-month high of $13.22.

Inogen (NASDAQ:INGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The firm had revenue of $92.28 million during the quarter, compared to the consensus estimate of $90.40 million. Inogen had a negative return on equity of 13.77% and a negative net margin of 7.58%. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts predict that Inogen, Inc will post -1.73 earnings per share for the current year.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.